Management of Anterior Open Bite in Obstructive Sleep Apnea

Craniofacial Risk Factors

Micrognathia and macroglossia significantly increase the risk of obstructive sleep apnea and are frequently associated with anterior open bite malocclusion. 1

Children with persistent OSA and anterior open bite linked to maxillary constriction should be considered for rapid maxillary expansion (RME) therapy. [2][3]
RME is optimally performed before puberty (typically ages 6–7 years) after eruption of the permanent first molars, using a cemented intra‑oral orthopedic appliance. [2][3]
Clinical indicators for RME include a high, narrow palate—often accompanied by a posterior crossbite—and documented OSA on sleep study. [2][3]
RME yields a mean reduction in the apnea‑hypopnea index of 3.3 events/h (95 % CI 1.8–4.8) and improves nocturnal oxygen saturation by 2.8 % (95 % CI 2.3–3.5). [2][3]
The activation protocol consists of screw activation for 1–2 weeks, followed by several weeks of retention without further activation to consolidate expansion. [2][3]

For adult patients with anterior open bite and mild‑to‑moderate OSA, mandibular advancement devices are an effective alternative to CPAP, though dental side effects (e.g., changes in overbite) must be monitored. [4][5]6
MADs function by stabilizing the mandible in a forward and slightly downward position, thereby advancing the mandible and associated upper‑airway structures to maintain patency during sleep. [4][5]
Clinical outcomes with MAD therapy include:
- Decreased frequency and duration of apneas, hypopneas, and respiratory effort‑related arousals (RERAs).
- Improved nocturnal oxygenation.
- Reduced daytime sleepiness and enhanced health‑related quality of life.
- These benefits are supported by randomized and observational studies. [5][6]
Adherence to MAD therapy is superior to CPAP, with patients using the device an average of 5.3 nights/week for 5.5 hours/night, compared with CPAP use of 4.2 nights/week for 3.6 hours/night. 7
After two years of continuous MAD use, patients experience a mean overbite reduction of 1.2 ± 1.1 mm and overjet reduction of 1.5 ± 1.5 mm, indicating modest but clinically relevant dental changes. 8

Severe pre‑existing anterior open bite is a relative contraindication for MAD therapy because of the risk of further vertical dental changes. [5][6]
Absolute contraindications for MADs include severe periodontal disease, advanced temporomandibular joint disorders, and insufficient dentition to retain the appliance. [5][6]
Recommended follow‑up schedule: dental and sleep‑medicine review every 6 months during the first year of MAD use, then annually, to assess occlusal changes and therapeutic efficacy. 4

A follow‑up sleep study (polysomnography or validated portable monitoring) should be performed after orthodontic or oral‑appliance treatment to confirm therapeutic benefit and guide further management. 4
Obesity remains the most important modifiable risk factor for OSA, present in 60–90 % of affected individuals; weight management should be integrated into all treatment plans. [1][9]